Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2026)

Takeda Pharmaceutical has reported Long-Term Investments for 10 years, with the latest figure at $63.2 million in Q2 2026.

• On a quarterly basis, Long-Term Investments fell 8.02% year-over-year to $63.2 million in Q2 2026; TTM through Jun 2026 was $63.2 million, a 8.02% decrease from a year earlier, with the FY2026 full-year figure at $56.1 million, down 20.91% from the prior year.
• Long-Term Investments was $63.2 million for Q2 2026 at Takeda Pharmaceutical, up from $56.1 million in the prior quarter.
• The five-year high for Long-Term Investments was $831.0 million in Q1 2022, with the low at $56.1 million in Q1 2026.
• Average Long-Term Investments over 5 years is $421.7 million, with a median of $584.7 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments increased 4.57% in 2023, then sank 88.32% in 2025.
• Over 5 years, Long-Term Investments stood at $668.4 million in 2022, then rose by 4.57% to $698.9 million in 2023, then slumped by 88.06% to $83.5 million in 2024, then decreased by 20.69% to $66.2 million in 2025, then slipped by 4.5% to $63.2 million in 2026.
• The last three Long-Term Investments figures came in at $63.2 million (Q2 2026), $56.1 million (Q1 2026), and $66.2 million (Q4 2025), per Business Quant data.